logo

  • The Company
    The Company
      • Promore Pharma in Brief
      • Vision and Strategy
      • Market
      • Team
      • Board of Directors
  • Projects
    Projects
      • Project Overview
      • Ensereptide – Prevention of Post-Surgical Adhesions and Scars
      • Ropocamptide – Healing of Chronic Wounds
      • Publications
  • Investors
    Investors
      • Promore Pharma on Nasdaq First North Growth Market
        • Certified Adviser
      • The Share
        • Shareholders
        • Warrant Programs
        • Share capital development
        • Analysts
      • Financial Reports
      • Press Releases
      • Prospectuses
      • Presentations and Events
      • Calendar
      • Subscribe
  • Corporate Governance
    Corporate Governance
      • Corporate Governance
      • General Meeting
        • General Meetings
      • Nomination Committee
        • Nomination Committees
      • The Board of Directors
        • Board of Directors
      • The Management
        • Management
      • Remunerations and Remuneration Committee
      • Auditor and Audit Committee
      • Articles of Association
      • Certificate of Registration
  • Media
    Media
      • Press Releases
      • Imagebank
      • Promore Pharma in Media
      • Subscribe
  • Contact
    Contact
      • Office
      • Investors
      • Media
Svenska
The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • Ensereptide – Prevention of Scarring
  • Ropocamptide – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
    • Certified Adviser
  • The Share
    • Shareholders
    • Warrant Programs
    • Share capital development
    • Analysts
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
    • General Meetings
  • Nomination Committee
    • Nomination Committees
  • The Board of Directors
    • Board of Directors
  • The Management
    • Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Media

  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe

Contact

Erik Magnusson

 Chief Financial Officer (CFO) +46 70 856 52 45

Press Releases

All press releases
  • Regulatory press releases
  • Non-regulatory press releases
2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2013
  • All years
February 28, 2023

Year-end report, 2022

February 27, 2023

Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Fourth Quarter 2022

February 27, 2023

Promore Pharma reaches the Clean File milestone in its phase II clinical trial with ensereptide

The Company
  • Promore Pharma in Brief
  • Vision and Strategy
  • Market
  • Team
  • Board of Directors
Projects
  • Project Overview
  • Ensereptide – Prevention of Scarring
  • Ropocamptide – Healing of Chronic Wounds
  • Publications
Investors
  • Promore Pharma on Nasdaq First North Growth Market
  • The Share
  • Financial Reports
  • Press Releases
  • Prospectuses
  • Presentations and Events
  • Calendar
  • Subscribe
Corporate Governance
  • Corporate Governance
  • General Meeting
  • Nomination Committee
  • The Board of Directors
  • The Management
  • Remunerations and Remuneration Committee
  • Auditor and Audit Committee
  • Articles of Association
  • Certificate of Registration
Media
  • Press Releases
  • Imagebank
  • Promore Pharma in Media
  • Subscribe
Contact
  • Office
  • Investors
  • Media

Promore Pharma AB. Address: Fogdevreten 2, SE-171 65 Solna, Sweden. Phone: +46 8 124 548 59. E-mail: info@promorepharma.com. Registration number: 556639-6809.

  • Personal data
  • About cookies